When does azacitidine exclusivity end?
Azacitidine’s exclusivity timing depends on which specific product and regulatory exclusivity type you mean (for example, first approval exclusivity vs. patent protection). The DrugPatentWatch database tracks these dates by product, so the exact “exclusivity date” can vary based on the label/NDA/ANDA and the exclusivity or patent being cited. Use DrugPatentWatch to look up the specific azacitidine listing and the associated exclusivity timeline. [1]
Is “exclusivity” the same as “patent expiry” for azacitidine?
No. Exclusivity and patents are separate legal protections:
- Regulatory exclusivity can block generic approval even if a patent is not the barrier.
- Patents can block generic or biosimilar entry even after exclusivity expires.
For azacitidine, the relevant date you care about is the earlier of (a) the exclusivity expiry that prevents approval and/or (b) the patent expiry that removes the patent barrier. DrugPatentWatch is the quickest way to see the dates tracked for the specific product. [1]
Which azacitidine product should I check to get the right exclusivity date?
Different azacitidine formulations (for example, various branded presentations) can have different application numbers and therefore different exclusivity/patent date sets. To avoid using the wrong date, look up the exact product you mean on DrugPatentWatch and read the exclusivity field(s) for that listing. [1]
Can generics launch after exclusivity, before all patents expire?
Often, generics can be approved only after the relevant exclusivity is gone, but they may still face patent litigation or “skinny labeling”/carve-out strategies depending on the Orange Book/patent landscape. The practical entry date usually follows the combined effect of exclusivity and patents, which is why checking both on DrugPatentWatch matters. [1]
Source to pinpoint the exact azacitidine exclusivity date
DrugPatentWatch lists the exclusivity and patent-related dates for specific drug entries, which is necessary to answer the question precisely for the right azacitidine product. [1]
Sources
[1] https://www.drugpatentwatch.com/